Semin Thromb Hemost 2000; Volume 26(Number s1): 047-052
DOI: 10.1055/s-2000-9493
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Prophylaxis and Treatment of Deep-Vein Thrombosis

Hans Klaus Breddin
  • International Institute for Thrombosis and Vascular Diseases, Frankfurt Main, Germany
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2000 (online)

 

ABSTRACT

In 1980, unfractionated heparin (UFH) was the established agent for the prophylaxis of venous thromboembolic (VTE) disease in patients undergoing general surgery. VTE prophylaxis was the first indication in which low-molecular-weight heparins (LMWHs) were tested. Approximately 40 trials have demonstrated that LMWHs are at least as effective and safe as UFH. LMWHs exhibit a number of advantages over UFH, including ease of administration, convenient once-daily dosing, and facilitation of outpatient management. The ideal time of administration and the dose of the initial one or two injections of LMWH remain unresolved issues. LMWHs are used with increasing frequency in the treatment of acute deep vein thrombosis (DVT), having been studied in comparison to UFH in 16 major clinical trials. LMWHs are at least as effective as UFH in the prevention of VTE, but higher doses than those used for prophylaxis are required. There is still an ongoing debate about whether the daily dose should be administered in one or two subcutaneous injections. In some recent studies, symptomatic new DVTs or pulmonary emboli (PE) were the primary end points, which had to be verified by objective methods, but such end points may be not be sensitive enough to detect major differences in the efficacy of different LMWHs.

REFERENCES

  • 1 Ockelford P A, Patterson J, Johns A S. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin).  Thromb Haemost . 1989;  62 1046-1049
  • 2 Pezzuoli G, Neri Serneri G G, Settembrini P. Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: A multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group.  Int Surg . 1989;  74 205-210
  • 3 Marassi A, Balzano G, Mari G. Prevention of postoperative deep vein thrombosis in cancer patients. A randomized trial with low molecular weight heparin (CY 216).  Int Surg . 1993;  78 166-170
  • 4 Nurmohamed M T, van Riel M A, Henkens C M. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.  Thromb Haemost . 1996;  75 233-238
  • 5 Valle I, Sola G, Origone A. Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep venous thrombosis.  Curr Med Res Opin . 1988;  11 80-86
  • 6 Bergqvist D, Flordal P A, Friberg B. Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial.  Vasa . 1996;  25 156-160
  • 7 Baca I, Schneider B, Kohler T. Prevention of thromboembolism in minimal invasive interventions and brief inpatient treatment. Results of a multicenter, prospective, randomized, controlled study with a low molecular weight heparin.  Chirurg . 1997;  68 1275-1280
  • 8 Adolf J, Knee H, Roder J D, van de Flierdt E, Siewert J R. Thromboembolism prophylaxis with low molecular weight heparin in abdominal surgery.  Dtsch Med Wochenschr . 1989;  114 48-53
  • 9 Kakkar V V, Boeckl O, Boneu B. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial.  World J Surg . 1997;  21 2-9
  • 10 Koppenhagen K, Matthes M, Häring R. Thromboseprophylaxe in der Abdominalchirurgie. Vergleich der Wirksamkeit und Verträglichkeit von niedermolekularem und unfraktioniertem Heparin.  Münch Med Woch . 1990;  132 677-680
  • 11 Koppenhagen K, Adolf J, Matthes M. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery.  Thromb Haemost . 1992;  67 627-630
  • 12 Heilmann L, Kruck M, Schindler A E. Thromboseprophylaxe in der Gynäkologie: Doppelblind-Vergleich zwischen niedermolekularem (LMWH) und unfraktioniertem (UFH) Heparin [Thrombosis prophylaxis in gynecology: A randomized double-blind study between low molecular weight heparin (LMWH) and unfractionated heparin (UFH)].  Geburtshilfe Frauenheilk . 1989;  49 803-807
  • 13 Heilmann L, von Tempelhoff F G, Herrle B. Low-Dose-Heparin versus niedermolekulares Heparin zur Thromboseprophylaxe in der operativen gynaekologischen Onkologie [Prevention of postoperative venous thrombosis. A randomised trial comparing low-dose heparin and low molecular weight heparin in gynaecological oncology].  Geburtshilfe Frauenheilk . 1997;  57 1-6
  • 14 Bergqvist D, Burmark U S, Frisell J. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis.  Br J Surg . 1986;  73 204-208
  • 15 Koller M, Schoch U, Buchmann P. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin.  Thromb Haemost . 1986;  56 243-246
  • 16 Bergqvist D, Matzsch T, Burmark U S. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis.  Br J Surg . 1988;  75 888-891
  • 17 Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs.  unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand . 1988;  67 99-103
  • 18 Fricker J P, Vergnes Y, Schach R. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery.  Eur J Clin Invest . 1988;  18 561-567
  • 19 Caen J P. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial.  Thromb Haemost . 1988;  59 216-220
  • 20 Hartl P, Brucke P, Dienstl E, Vinazzer H. Prophylaxis of thromboembolism in general surgery: Comparison between standard heparin and Fragmin.  Thromb Res . 1990;  57 577-584
  • 21 Kakkar V V, Cohen A T, Edmonson R A. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group.  Lancet . 1993;  341 259-265
  • 22 Samama M, Bernard P, Bonnardot J P. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis.  Br J Surg . 1988;  75 128-131
  • 23 Gazzaniga G M, Angelini G, Pastorino G. Enoxaparin in the prevention of deep venous thrombosis after major surgery: Multicentric study. The Italian Study Group.  Int Surg . 1993;  78 271-275
  • 24 Nurmohamed M T, Verhaeghe R, Haas S. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery.  Am J Surg . 1995;  169 567-571
  • 25 McLeod R, Geerts W, Sniderman K. Thromboprophylaxis in colorectal surgery-A randomized trial comparing low dose heparin to enoxaparin.  Haemostasis. 1996;  26 290 ((Abstr))
  • 26 ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment.  Br J Surg . 1997;  84 1099-1103
  • 27 Liezorovicz A, Picolet H, Peyrieux J C, Boissel J P. Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group.  Br J Surg . 1991;  78 412-416
  • 28 Bara L, Leizorovicz A, Picolet H, Samama M. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin Study Group.  Thromb Res . 1992;  65 641-650
  • 29 Kakkar V V, Murray W J. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: A co-operative study.  Br J Surg . 1985;  72 786-791
  • 30 The European Fraxiparin Study (EFS) Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery.  Br J Surg . 1988;  75 1058-1063
  • 31 Eurin B. Efficacy and tolerance of Fraxiparine in the prevention of deep vein thrombosis in general surgery performed with medullar conduction anesthesia.  Ann Fr Anesth Reanim . 1994;  13 311-317
  • 32 Bounameaux H, Huber O, Khabiri E. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin.  Arch Surg . 1993;  128 326-328
  • 33 Hoffmann R, Largiadèr F. Die Thromboembolieprophylaxe und der Chirurg-zwei Risikofaktoren der postoperativen Blutung?.  <~>[Thromboembolism prophylaxis and the surgeon-two risk factors of postoperative bleeding?]. Aktuelle Chirurgie . 1995;  30 264-270
  • 34 Hull R D, Raskob G E, Rosenbloom D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.  N Engl J Med . 1990;  322 1260-1264
  • 35 Holmostrom M, Berglund M C, Granquist S. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg.  Thromb Res . 1992;  67 49-55
  • 36 Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux J F. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group.  Thromb Haemost . 1994;  71 698-702
  • 37 Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.  Thromb Haemost . 1994;  72 186-190
  • 38 Ninet J, Bachet P H, Prandoni P. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis.  Thromb Haemost . 1991;  65 251-256
  • 39 Prandoni P, Lensing A W, Buller H R. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.  Lancet . 1992;  339 441-445
  • 40 Lopaciuk S, Meissner A J, Filipecki S. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial.  Thromb Haemost . 1992;  68 14-18
  • 41 Janvier G, Winnock S, Dugrais G. Treatment of deep venous thrombosis with a very low molecular weight heparin fragment (CY 222).  Haemostasis . 1987;  17 49-58
  • 42 Janvier G, Freyburger G, Winnock S. An open trial of enoxaparin in the treatment of deep vein thrombosis of the leg.  Haemostasis . 1991;  21 161-168
  • 43 Simonneau G, Charbonnier B, Decousus H. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.  Arch Intern Med . 1993;  153 1541-1546
  • 44 Pini M, Aiello S, Manotti C. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis.  Thromb Haemost . 1994;  72 191-197
  • 45 Hull R D, Raskob G E, Pineo G F. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.  N Engl J Med . 1992;  326 975-982
  • 46 Harenberg J, Huck K, Bratsch H. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis.  Haemostasis . 1990;  205(suppl 1) 205-219
  • 47 Levine M, Gent M, Hirsh J. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  N Engl J Med . 1996;  334 677-681
  • 48 Koopman M MW, Prandoni P, Piovella F. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.  N Engl J Med . 1996;  334 682-687
  • 49 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.  N Engl J Med . 1997;  337 657-662
  • 50 Kirchmaier C M, Wolf H, Schäfer H, Ehlers B, Breddin H K, for the Certoparin-Study group. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis.  Int Angiol . 1998;  17 135-1451